VIB305
/ Vibrant Sciences Limited
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
March 24, 2026
A Clinical Study to Evaluate the Safety of VIB305 in Patients With Advanced Solid Tumors
(clinicaltrials.gov)
- P1/2 | N=146 | Recruiting | Sponsor: Vibrant Sciences Limited | Not yet recruiting ➔ Recruiting
Enrollment open • Oncology • Solid Tumor
January 12, 2026
Vibrant Therapeutics Raises $61M and Appoints Han Lee, Ph.D. as Co-CEO
(Businesswire)
- "...U.S. Food and Drug Administration (FDA) has accepted the Investigational New Drug (IND) application for its lead program, VIB305, for the treatment of EGFR-positive solid tumors....Proceeds from the financing will be used to advance Vibrant’s robust pipeline, as well as further develop its proprietary next-generation drug design platform and expand the company’s team to support continued growth and global development activities."
Financing • IND • Solid Tumor
1 to 2
Of
2
Go to page
1